American multinational pharma leader behind GLP-1 drugs and blockbuster therapies
Recent studies have shown significant advances in gene therapy for hearing loss and eye conditions, as well as promising research on reversing brain inflammation linked to aging. Meanwhile, new evidence questions the effectiveness of Alzheimer’s drugs, highlighting ongoing challenges in neurodegenerative treatments. Today's date is Mon, 27 Apr 2026 11:37:39 +0100.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
A wave of AI-related IPOs from SpaceX, Anthropic and OpenAI is unfolding, with markets facing a flood of new stock. Retail demand remains strong for SpaceX, but analysts warn supply could overwhelm demand, pressuring prices and testing market resilience.
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.
Three articles report on cutting-edge biotech and AI-driven medicine: base editing in embryos stirs debate over cures and designer babies; Google-backed AI seeks clinical trust; Life Biosciences tests cellular reprogramming in humans to combat aging and glaucoma.
Markets are stabilising after a stretch of high activity in tech options, with traders shifting focus as implied volatility cools. Small caps are leading potential next moves, while global equities reflect a policy-led, carry-friendly regime.
Pennsylvania has rolled out stricter guardrails for data center projects, including energy cost commitments, community engagement, and environmental protections. The move aims to accelerate development while addressing local concerns. Projects like Boson and The Highland are cited as tests of the new framework amid bipartisan push for faster permitting.
POLITICO, Independent, Business Insider UK and others report on RAISE US, a bipartisan nonprofit led by Gina Raimondo and Eric Holcomb. The group mobilizes $500m+ from tech firms to fund workforce programs, pilots in Arkansas, Maryland, Utah and Connecticut, and policy work to shield workers from AI disruption.
The UK–US pharmaceutical deal has led to a BMJ analysis predicting the NHS will divert billions to fund new medicines, risking hundreds of thousands of excess deaths by 2036, with the toll higher if social care funding is included.
The 340B program, which lets hospitals buy discounted outpatient drugs for low-income patients, is facing a new CMS rule changing reimbursement formulas to reduce payments by about 40%. The move aims to lower patient costs but could shrink hospital revenues and affect services and jobs. The rule follows an executive order in 2025 and reflects ongoing political battles between hospitals and the pharmaceutical industry.
Eli Lilly has announced an all-cash deal to acquire AtaiBeckley for up to $2.8 billion upfront, with potential milestone payments. AtaiBeckley’s lead drug, a DMT-related nasal spray for treatment-resistant depression, is in Phase 3, with initial results expected in 2029. The deal signals growing pharma interest in psychedelic therapies amid regulatory momentum.